Hostname: page-component-8448b6f56d-c47g7 Total loading time: 0 Render date: 2024-04-23T18:06:12.161Z Has data issue: false hasContentIssue false
  • English
  • Français

Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets

Published online by Cambridge University Press:  30 August 2007

Marc-antoine Crocq ,
Marie-Sa Guillon ,
Paul Ernest Bailey  and
Dominique Provost
Marc-antoine Crocq*
Affiliation:
Centre Hospitalier, Service de Psychiatrie de l'Adolescent, BP29, 68250Rouffach, France
Marie-Sa Guillon
Affiliation:
Centre Hospitalier, Service de Psychiatrie de l'Adolescent, BP29, 68250Rouffach, France
Paul Ernest Bailey
Affiliation:
Centre Hospitalier, Service de Psychiatrie de l'Adolescent, BP29, 68250Rouffach, France
Dominique Provost
Affiliation:
Centre Hospitalier, Service de Psychiatrie de l'Adolescent, BP29, 68250Rouffach, France
*
∗Corresponding author. Tel.: +33 6 62 33 56 84; fax: +33 3 89 78 72 00. E-mail address: ma.crocq@ch-rouffach.fr (M.-A. Crocq).
Get access

Abstract

We compared the changes in weight (kg) and body mass index (BMI) (kg/m2) in 52 hospitalized adolescents between baseline and after 12 weeks of monotherapy with either (i) olanzapine (OLZ) orally disintegrating tablets (ODT) (N = 16; 16.6 mg/day ± 4.4 [SD]), or (ii) OLZ standard oral tablets (SOT) (N = 10; 18.0 mg/day ± 4.2), or (iii) risperidone (N = 26; 2.8 mg/day ± 1.2). Significantly greater increases in mean weight and BMI were observed in the patients treated with OLZ SOT (8.9 ± 5.1 [SD] kg; 1.9 ± 0.6 kg/m2, respectively) than in those with ODT (3.0 ± 2.1 kg; 1.1 ± 0.8 kg/m2). Similarly, OLZ ODT treatment was associated with significantly greater increases in weight and BMI than risperidone (1.0 ± 1.8 kg; 0.4 ± 0.7 kg/m2). These findings suggest that adolescents gain less weight with OLZ ODT than OLZ SOT, possibly because the former formulation shortens the time of interaction with digestive serotonin receptors mediating satiety.

Keywords

OlanzapineOrally disintegrating tabletsWeight gainBMIAdolescents
Type
Case report
Information
European Psychiatry , Volume 22 , Issue 7 , October 2007 , pp. 453 - 454
Copyright
Copyright © Elsevier Masson SAS 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Arranz, B., San, L., Dueñas, R.M., Centeno, M., Ramirez, N., Salavert, J.et al.Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol Clin Exp 2007;22:11–15.CrossRefGoogle ScholarPubMed
De Haan, L., van Amelsvoort, T., Rosien, K., Linszen, D.Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004;175:389–390.CrossRefGoogle ScholarPubMed
Eberle-Wang, K., Braun, B.T., Simansky, K.J.Serotonin contracts the isolated rat pylorus via a 5-HT2-like receptor. Am J Physiol Regul integr Comp Physiol 1994;266:284–291.CrossRefGoogle Scholar
Markowitz, J.S., DeVane, C.L., Malcolm, R.J., Gefroh, H.A., Wang, J.S., Zhu, H.J.et al.Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 2006;46:164–171.CrossRefGoogle ScholarPubMed
Templeman, L.A., Reynolds, G.P., Arranz, B., San, L.Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005;15:195–200.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.